Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC-MedSci.cn

Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC

Hayashi, H; Yu, HA; Baik, C; Gold, K; Johnson, ML; Koczywas, M; Murakami, H; Nishio, M; Steuer, C; Su, WC; Yang, JCH; Karam, S; Qui, ZH; Qiu, Y; Chen, SQ; Yu, CN; Janne, PA

ANNALS OF ONCOLOGY, 2021; 32 (): S318

科室
- - 订阅+
  - 更多科室
工具
服务